Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 0.91
- Piotroski Score 3.00
- Grade Overweight
- Symbol (RCEL)
- Company AVITA Medical, Inc.
- Price $10.73
- Changes Percentage (-0.09%)
- Change -$0.01
- Day Low $10.58
- Day High $10.95
- Year High $18.93
AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients eighteen years and older. The company has a research collaboration with the University of Colorado School of Medicine to establish pre-clinical proof-of-concept for a spray-on treatment of genetically corrected cells; and a research collaboration with Houston Methodist Research Institute to explore molecular reversal of cellular aging through a novel cell suspension delivery system. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical Inc. in December 2020. AVITA Medical Inc. was incorporated in 2000 and is based in Valencia, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/06/2024
- Fiscal Year End N/A
- Average Stock Price Target $9.00
- High Stock Price Target $9.00
- Low Stock Price Target $9.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.76
- Trailing P/E Ratio -5.2
- Forward P/E Ratio -5.2
- P/E Growth -5.2
- Net Income $-39,168,218
Income Statement
Quarterly
Annual
Latest News of RCEL
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Two teen centre-backs and a need to rest stars showed Barcelona's limits against Osasuna
Barcelona's coach Flick rotated his team heavily for a La Liga match against Osasuna, with young players like Dominguez and Cubarsi starting. Despite a 4-2 loss, Flick defended his decision, citing th...
By The New York Times | 1 day ago -
Marcel Reed throws for 2 touchdowns and runs for another in No. 24 Aggies' 21-17 win over Arkansas
Marcel Reed led Texas A&M to a 21-17 victory over Arkansas with two passing touchdowns and one rushing touchdown. The Aggies won for the 12th time in 13 meetings at AT&T Stadium....
By AP NEWS | 2 days ago -
FC Barcelona Boss Flick Reacts To First Loss Of Season: 'We Made A Lot Of Mistakes'
FC Barcelona manager Hansi Flick acknowledged the team's mistakes in their 4-2 loss to Osasuna, attributing it to necessary player rotations. Despite the defeat, he remains focused on upcoming matches...
By Forbes | 2 days ago
